J. Ludwig

Publications71
h-index24
Citations6,322
Highly Influential Citations237
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • R. Benjamin
  • 651 Publications, 29,175 Citations
  • V. Subbiah
  • 477 Publications, 5,983 Citations
  • R. Kurzrock
  • 1,320 Publications, 50,055 Citations
  • S. Patel
  • 249 Publications, 12,453 Citations
  • Publications
  • Influence
Targeting multidrug resistance in cancer
Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy. In most cases, multiple drugs are used, as resistance to single agents occurs almost universally. For this… Expand
  • 2,711
  • 111
Biomarkers in Cancer Staging, Prognosis and Treatment Selection
Advances in genomics, proteomics and molecular pathology have generated many candidate biomarkers with potential clinical value. Their use for cancer staging and personalization of therapy at the… Expand
  • 1,376
  • 34
Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future
  • J. Ludwig
  • Medicine
  • Current opinion in oncology
  • 1 July 2008
Purpose of review As the second most common bone malignancy in children and adolescents, Ewing sarcoma family tumors represent almost 3% of pediatric cancers. Multidisciplinary management of patients… Expand
  • 165
  • 13
Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.
ATP-binding cassette (ABC) proteins include the best known mediators of resistance to anticancer drugs. In particular, ABCB1 [MDR1/P-glycoprotein (P-gp)] extrudes many types of drugs from cancer… Expand
  • 144
  • 10
  • PDF
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
BACKGROUND Preclinical studies have shown synergistic antitumour activity by inhibition of insulin-like growth factor-1 receptor (IGF-1R) and mTOR. The expression of IGF-1R seems to be crucial for… Expand
  • 140
  • 9
  • PDF
Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor
Hemangiopericytomas and malignant solitary fibrous tumors (HPC/SFT) are rare, closely related sarcomas with unpredictable behavior that respond infrequently to chemotherapy. An optimal systemic… Expand
  • 154
  • 7
Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors
Purpose: Temsirolimus was combined with cixutumumab, a fully human IgG1 monoclonal antibody directed at the insulin growth factor-1 receptor (IGF-1R). Experimental Design: Patients received… Expand
  • 150
  • 5
  • PDF
Universal marker and detection tool for human sarcoma circulating tumor cells.
To date, no specific marker exists for the detection of circulating tumor cells (CTC) from different types of sarcomas, though tools are available for detection of CTCs in peripheral blood of… Expand
  • 93
  • 5
  • PDF
Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor.
BACKGROUND We sought to investigate the characteristics and survival rate of patients with gastrointestinal stromal tumor (GIST) associated with other primary malignancies. PATIENTS AND METHODS A… Expand
  • 82
  • 5
Complete Cytoreduction and HIPEC Improves Survival in Desmoplastic Small Round Cell Tumor
BackgroundDesmoplastic small round cell tumor (DSRCT) is a rare tumor of adolescents and young adults. Less than 100 cases per year are reported in North America. Extensive peritoneal metastases are… Expand
  • 81
  • 5